Japan's Chuikyo discusses NIH drug pricing reform and market expansion

2 March 2009

Japan's Central Social Insurance Medical Council (Chuikyo) has started discussions on a re-calculation method for pharmaceutical products in  relation to market expansion, as part of the National Health Insurance  drug pricing reform for the fiscal year 2010 through its Expert  Committee on the NHI Drug pricing.

The issue has been the subject of considerable debate between the  government, the pharmaceutical industry and the various health care  payer organizations, which have expressed strongly disparate views on  the calculation system (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight